The departing Federal Reserve chair declines to remain on the board, citing concerns over President Trump's legal challenges to the central bank's operational independence.
The departing Federal Reserve chair has decided not to remain on the board, citing concerns over President Trump's legal challenges to the institution's operational structure.
What happened
The departing Federal Reserve chair has decided not to remain on the board, citing concerns over President Trump's legal challenges to the institution's operational structure.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
The U.S. is intensifying efforts to block Iran's oil trade with China as part of a strategy to cut off the country's primary financial lifeline.
The United States is increasing efforts to disrupt Iran's oil exports to China, targeting the country's primary source of revenue.
Federal Reserve official Neel Kashkari says the central bank may need to raise interest rates in some scenarios. The comments highlight potential shifts in monetary policy outlook.
Federal Reserve official Neel Kashkari stated that the central bank may need to increase interest rates under certain economic scenarios.
US Treasury Secretary Bessent says he is optimistic that Federal Reserve Chair Jerome Powell will step down in the near term.
US Treasury Secretary Bessent expressed optimism that Federal Reserve Chair Jerome Powell will step down from his position in the near term.
UCB to acquire Candid Therapeutics in deal worth up to $2.2 billion. The Belgian pharmaceutical group announced the agreement to expand its portfolio.
Belgian pharmaceutical company UCB has announced an agreement to acquire Candid Therapeutics in a deal valued at up to $2.2 billion.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.